Corrigendum to "CDYL loss promotes cervical cancer aggression by increasing PD-L1 expression via the suppression of IRF2BP2 transcription" [Transl Oncol. 2024 Sep;47:102038 /PMID: 38991463].

IF 4.5 2区医学 Q1 ONCOLOGY Translational Oncology Pub Date : 2025-01-01 Epub Date: 2024-11-30 DOI:10.1016/j.tranon.2024.102219

Ying Cui, Yuxi Zhao, Guihua Shen, Qiubo Lv, Linlin Ma

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Translational Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

7.20

自引率

2.00%

发文量

314

审稿时长

6-12 weeks

期刊介绍： Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.

期刊最新文献

m6A methyltransferase METTL3 promotes non-small-cell lung carcinoma progression by inhibiting the RIG-I-MAVS innate immune pathway. 4'-Demethylpodophyllotoxin functions as a mechanism-driven therapy by targeting the PI3K-AKT pathway in Colorectal cancer. Indirect targeting of MYC and direct targeting in combination with chemotherapies are more effective than direct mono-targeting in triple negative breast cancer. Corrigendum to "ACAT1 suppresses clear cell renal cell carcinoma progression by AMPK mediated fatty acid metabolism" [Transl Oncol 47:102043(Sep 2024) 102043]. Corrigendum to "CDYL loss promotes cervical cancer aggression by increasing PD-L1 expression via the suppression of IRF2BP2 transcription" [Transl Oncol. 2024 Sep;47:102038 /PMID: 38991463].